Sanofi’s Soliqua 100/33 for Type 2 diabetes gets FDA nod

SILVER SPRING, Md. — The Food and Drug Administration has approved Sanofi’s Soliqua 100/33 (insulin glargine 100 units/mL and lixisenatide 33mcg/mL), the company announced Monday. The drug is indicated to treat adults with Type 2 diabetes that’s inadequately controlled on basal insulin or lixisenatide. 

 

"Sanofi continues to be a pioneer in developing diabetes therapies and in bringing forward new treatment options for the approximately 50 percent of patients whose blood sugar levels remain uncontrolled on daily basal insulin,” Sanofi president of global research and development Elias Zerhouni said. “Soliqua 100/33 is an alternate new approach that can help adults living with type 2 diabetes uncontrolled on basal insulin or lixisenatide to reach their treatment goal.”

 

Soliqua 100/33 combines Lantus and lixisenatide, a GLP-1 receptor agonist, in a once-daily injection. The injection will be delivered in pre-filled pens using SoloStar technology, the company said. The drug will be available for U.S. retailn pharmacies in January 2017.